Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

XOMA starts XOMA-123 phase II study

June 29, 2016

Bristol-Myers Squibb receives new breakthrough therapy designation for Opdivo

June 28, 2016

EMA recommends approval of Keytruda for advanced NSCLC

June 28, 2016

Puma submits MAA to the EMA for neratinib

June 28, 2016

Xencor and Novartis establish bispecific collaboration

June 28, 2016

Janssen initiates first-in-human study of JNJ-61186372 in advanced NSCLC

June 28, 2016

Compugen announces new lead candidate

June 27, 2016

Epizyme closes deal with Genentech for tazemetostat + atezolizumab study

June 23, 2016

STAT3 inhibition shows positive preclinical results for the treatment of breast cancer

June 23, 2016

Incyte initiates phase I/II study of INCAGN-01876 for advanced or metastatic solid tumors

June 23, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...